Experience

Davis Polk advised the underwriters in connection with an SEC-registered offering by AMAG Pharmaceuticals, Inc. of $300 million aggregate principal amount of its 3.25% convertible…

Davis Polk advised the joint book-running managers in connection with a $2.25 billion registered offering by Eli Lilly and Company of $750 million principal amount of its 2.350% notes…

Davis Polk advised the representative of the initial purchasers in a Rule 144A offering by Flexion Therapeutics, Inc. of $201.25 million aggregate principal amount of its 3.375% convertible…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 5,050,505 shares of common stock of…

Davis Polk advised the sole book-running manager in connection with Galapagos NV’s offering of 4,312,500 ordinary shares in the form of American depositary shares, which includes the full…

Davis Polk advised the underwriters in connection with a secondary offering of 7,500,000 shares of Class A common stock of Evolent Health, Inc. by certain of Evolent’s existing stockholders…

Davis Polk advised the joint lead dealer managers in connection with the registered offers by Abbott Laboratories to exchange certain outstanding debt securities of St. Jude Medical,…

Davis Polk advised Penumbra, Inc. on its SEC-registered follow-on public offering of 1,495,000 shares of common stock for an aggregate price to the public of approximately $113.62 million…

Davis Polk advised the active joint book-running managers and representatives of the underwriters in connection with the $90 million follow-on offering of 4,000,000 shares of common stock…

Davis Polk advised Valeant Pharmaceuticals International, Inc. in connection with a refinancing transaction pursuant to which Valeant issued new debt to refinance its shorter term…